Adiponectin in insulin resistance: lessons from translational research.

Adiponectin is an adipose tissue-secreted endogenous insulin sensitizer, which plays a key role as a mediator of peroxisome proliferator-activated receptor gamma action. Adiponectin alters glucose metabolism and insulin sensitivity, exhibits antiinflammatory and antiatherogenic properties, and has been linked to several malignancies. Circulating concentrations of adiponectin are determined primarily by genetic factors, nutrition, exercise, and abdominal adiposity. Adiponectin concentrations are lower in subjects with obesity, metabolic syndrome, and cardiovascular disease. Adiponectin knockout mice manifest glucose intolerance, insulin resistance, and hyperlipidemia and tend to develop malignancies especially when on high-fat diets. Animal studies have also shown beneficial effects of adiponectin in rodents in vivo. Circulating concentrations of adiponectin are lower in patients with diabetes, cardiovascular disease, and several malignancies. Studies to date provide promising results for the diagnostic and therapeutic role of adiponectin in obesity, insulin resistance, diabetes, cardiovascular disease, and obesity-associated malignancies.

[1]  L. Higgins,et al.  Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. , 2010, The American journal of clinical nutrition.

[2]  C. Mantzoros,et al.  Total and High–Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program: Comparative Evaluation of Three Assays , 2007, Diabetes Care.

[3]  C. Mantzoros,et al.  The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer , 2008, PPAR research.

[4]  W. W. Cheatham.  Peroxisome proliferator-activated receptor translational research and clinical experience. , 2010, The American journal of clinical nutrition.

[5]  M. Lombès,et al.  Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin , 2002, FEBS letters.

[6]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[7]  Philippe Froguel,et al.  Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.

[8]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[9]  Harvey F Lodish,et al.  Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. , 2003, Cytokine & growth factor reviews.

[10]  S. Kihara,et al.  PARADOXICAL DECREASE OF OBTAIN A BETTER UNDERSTANDING OF ADIPONECTIN'S ROLE IN THE ADIPOSE-SPECIFIC PROTEIN, ADIPONECTIN IN OBESITY , 1999 .

[11]  C. Mantzoros,et al.  Serum Adiponectin Concentrations and Tissue Expression of Adiponectin Receptors Are Reduced in Patients with Prostate Cancer: A Case Control Study , 2007, Cancer Epidemiology Biomarkers & Prevention.

[12]  Kohjiro Ueki,et al.  Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. , 2007, Cell metabolism.

[13]  F. Hu,et al.  Coffee Consumption Is Associated With Higher Plasma Adiponectin Concentrations in Women With or Without Type 2 Diabetes , 2008, Diabetes Care.

[14]  C. Mantzoros,et al.  Adiponectin and breast cancer risk. , 2004, The Journal of clinical endocrinology and metabolism.

[15]  J. Fenton,et al.  Adiponectin blocks multiple signaling cascades associated with leptin‐induced cell proliferation in ApcMin/+ colon epithelial cells , 2008, International journal of cancer.

[16]  T. Kadowaki,et al.  Adiponectin and adiponectin receptors in obesity-linked insulin resistance. , 2007, Novartis Foundation symposium.

[17]  G. Blackburn.  From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor gamma modulators. , 2010, The American journal of clinical nutrition.

[18]  C. Proud,et al.  When translation meets transformation: the mTOR story , 2006, Oncogene.

[19]  C. Mantzoros,et al.  Total and High–Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program , 2007, Diabetes Care.

[20]  Philipp E. Scherer,et al.  A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.

[21]  J. Bub,et al.  Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. , 2005, Biochemical and biophysical research communications.

[22]  Y. Nakano,et al.  Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. , 1996, Journal of biochemistry.

[23]  C. Mantzoros,et al.  Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. , 2003, The Journal of clinical endocrinology and metabolism.

[24]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[25]  E. Rimm,et al.  Adiponectin and future coronary heart disease events among men with type 2 diabetes. , 2005, Diabetes.

[26]  P. Scherer,et al.  ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism , 2002, Trends in Endocrinology & Metabolism.

[27]  J. Manson,et al.  Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. , 2005, The Journal of clinical endocrinology and metabolism.

[28]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[29]  Gurmit Singh,et al.  Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. , 2008, European urology.

[30]  S. Kliewer,et al.  Fibroblast growth factor 21: from pharmacology to physiology. , 2010, The American journal of clinical nutrition.

[31]  M. Stampfer,et al.  A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[32]  H. Ostrer,et al.  Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. , 2008, Cancer research.

[33]  Nader Rifai,et al.  Association between dietary factors and plasma adiponectin concentrations in men. , 2005, The American journal of clinical nutrition.

[34]  S. Brichard,et al.  Hyperadiponectinaemia in anorexia nervosa , 2003, Clinical endocrinology.

[35]  C. Mantzoros,et al.  Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. , 2006, The Journal of clinical endocrinology and metabolism.

[36]  C. Mantzoros,et al.  Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study , 2009, Cancer Causes & Control.

[37]  S. O’Rahilly,et al.  Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. , 2002, Endocrinology.

[38]  J. Manson,et al.  Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. , 2006, The American journal of clinical nutrition.

[39]  W. Willett,et al.  Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. , 2005, Journal of the National Cancer Institute.

[40]  C. Friedenreich,et al.  Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. , 2007, The Journal of clinical endocrinology and metabolism.

[41]  B. Goldstein,et al.  Adiponectin: A novel adipokine linking adipocytes and vascular function. , 2004, The Journal of clinical endocrinology and metabolism.

[42]  M. Cnop,et al.  Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex , 2003, Diabetologia.

[43]  S. Kihara,et al.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms , 2005, Nature Medicine.

[44]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB–Binding Protein and Regulates Growth Factor–Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell , 2002, Circulation.

[45]  H. Nagawa,et al.  Plasma adiponectin and gastric cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  N. Ruderman,et al.  AMPK, the metabolic syndrome and cancer. , 2005, Trends in pharmacological sciences.

[47]  C. Mantzoros,et al.  Circulating adiponectin and endometrial cancer risk. , 2004, The Journal of clinical endocrinology and metabolism.

[48]  F. Hu,et al.  Total and High-Molecular-Weight Adiponectin and Resistin in Relation to the Risk for Type 2 Diabetes in Women , 2008, Annals of Internal Medicine.

[49]  C. Mantzoros,et al.  Responsiveness to peripherally administered melanocortins in lean and obese mice. , 2004, Diabetes.

[50]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[51]  C. Mantzoros,et al.  Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. , 2008, Endocrine-related cancer.

[52]  R. A. Norman,et al.  The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. , 2002, Diabetes.

[53]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[54]  C. Mantzoros,et al.  Circulating Adiponectin and Leptin in Relation to Myelodysplastic Syndrome: A Case-Control Study , 2008, Oncology.

[55]  S. O’Rahilly,et al.  Induction of Adipocyte Complement-related Protein of 30 Kilodaltons by Ppar␥ Agonists: a Potential Mechanism of Insulin Sensitization , 2022 .

[56]  A. Horiguchi,et al.  Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. , 2008, Japanese journal of clinical oncology.

[57]  Hirokazu Takahashi,et al.  Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition , 2008, Gut.

[58]  C. Mantzoros,et al.  Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. , 2007, American journal of physiology. Endocrinology and metabolism.

[59]  Hui Chen,et al.  Adiponectin Stimulates Production of Nitric Oxide in Vascular Endothelial Cells* , 2003, Journal of Biological Chemistry.